

2 September 2010

Exceptional VitroGro® Clinical Results Continue


Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has today released outstanding results from an additional cohort of 5 chronic venous ulcer patients in the Australian human trial of VitroGro®, bringing the Australian study total to 27 patients.

The clinical research photography below shows typical results from this clinical trial.


Day 0

Day 24


100% healed after no response to one month of expert treatment



76% healed after ulcer duration of six months



100% healed after no response to six months of expert care



These excellent results with only 24 days treatment with VitroGro® twice per week include:

- Complete healing of 5 out of 27 patients
- Average area of ulcer healing: 41%
- Statistical significance: $p < 0.0001$

The venous ulcer patients who took part in this clinical trial were medically challenging with:

- Average age of 70 years
- Average venous ulcer duration of 12 months
- Average time during which the venous ulcers were unresponsive to compression dressings (the current state of the art treatment) prior to joining the VitroGro® trial: 10 months

The CEO of Tissue Therapies, Dr Steven Mercer said, "Compared to currently available treatments for chronic venous ulcers, these are superb results. This data complements the outstanding clinical outcomes achieved with VitroGro® for the extremely challenging patients in the Canadian human trial (ASX: TIS CEO AGM Presentation 27 Nov. 2009) and we now have excellent clinical data from a total of 37 patients."

This human trial of VitroGro® was conducted by Professor Michael Stacey at the Vascular Research Laboratory in Western Australia and statistical analysis was performed by staff from the University of Western Australia.

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell-based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com